First-Line Pembrolizumab in PD-L1 Positive Non-Small Cell Lung Cancer- A Cost-Effectiveness Analysis from A UK Healthcare Perspective

Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.006
https://www.valueinhealthjournal.com/article/S1098-3015(17)30339-X/fulltext
Title : First-Line Pembrolizumab in PD-L1 Positive Non-Small Cell Lung Cancer- A Cost-Effectiveness Analysis from A UK Healthcare Perspective
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30339-X&doi=10.1016/j.jval.2017.08.006
First page : A399
Section Title : BREAKOUT SESSION I
Open access? : No
Section Order : 4
Categories :
Tags :
Regions :
ViH Article Tags :